Trogenix

Trogenix is pioneering a new frontier in cancer treatment with its proprietary Synthetic Super Enhancers (SSEs) technology. These engineered DNA elements are designed to activate only in diseased cell states, providing a highly selective approach to gene control. The company's flagship platform, Odysseus, is uniquely positioned to develop precision cancer therapies that target specific diseased cell behaviors. By combining payloads that expose cancer to the immune system and destroy tumor cells, Trogenix offers a novel therapeutic strategy akin to a Trojan horse, hiding within tumors to awaken the immune system and provide long-term protection against recurrence. The company's lead program focuses on glioblastoma (GBM), a highly aggressive brain cancer with significant unmet medical needs. Current treatments for GBM offer limited efficacy, with only 25% of patients surviving beyond one year. Trogenix's GBM therapy has demonstrated curative potential in preclinical studies, aiming to extend survival rates significantly. Beyond oncology, Trogenix is exploring applications in regenerative medicine, leveraging the versatility of its SSE technology to adapt to various medical challenges. Founded in 2023 by world-renowned experts, Trogenix is on a mission to transform cancer treatment paradigms and offer hope where traditional therapies fall short. Keywords: cancer treatment, Synthetic Super Enhancers, gene control, immune activation, glioblastoma, precision therapy, DNA elements, tumor targeting, regenerative medicine, Odysseus platform.